Novo deal with Pioneering Medicines opens door to array of technologies

Novo Nordisk is not just getting access to one new technology but a whole portfolio of technology plays via a partnership with Flagship’s Pioneering Medicines unit, the first major deal for the firm’s drug development platform.

Novo Nordisk A/S (CSE:NOVO; NYSE:NVO) and Pioneering Medicines partnered on Tuesday to discover and develop therapies for cardiovascular, metabolic and rare diseases. The deal gives Novo access to Flagship’s 41 portfolio companies to identify the best therapeutic approaches to address a specific disease biology or therapeutic target. Novo will provide funding for the research programs and retain an exclusive option to license the resulting assets...